Ocular iontophoresis

Ophthalmic Drug Delivery Systems, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 365-408

  Myles, Marvin E ^a   Loutsch, Jeannette M ^a   Higaki, Shiro ^a   Hill, James M ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85058085236     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (173)

1. Sing, P., and Maibach, H. I. (1994). Iontophoresis in drug delivery: Basic principles and applications. Crit. Rev. Therp. Drug Carrier System., 11: 161-213.
2. Guy, R. H., Kalia, Y. N., Delgado-Charro, M. B., Merino, V., Lopez, A., and Marro, D. (2000). Iontophoresis: electrorepulsion and electroosmosis. J. Control Releas., 64: 129-132.
3. Merino, V., Kalia, Y. N., and Guy, R. H. (1997). Transdermal therapy and diagnosis by iontophoresis. Trends Biotechno., 15: 288-290.
4. Duke-Elder, S. (1962). Iontophoresis. In The Foundations of Ophthalmology, Vol. 7. C. V. Mosby, St. Louis, pp. 507-514.
5. Harris, R. (1967). Iontophoresis, in Therapeutic Electricity and Ultraviolet Radiation (S. Licht, ed.), Waverly Press, Baltimore, pp. 156-178.
6. Banga, A. K., and Chien, Y. W. (1988). Iontophoretic delivery of drugs: fundamentals, development and biomedical applications. J. Control Release, 7: 1-24.
7. Nair, V, Pillai, O, Poduri, R., and Panchagnula, R. (1999). Transdermal iontophoresis. Part I: Basic principles and considerations. Meth. Find. Exp. Clin. Pharmacol., 21: 139-151.
8. Tyle, P. (1986). Iontophoretic devices for drug delivery. Review. Pharm. Res., 3: 318-326.
9. Garrison, J. (1998). Iontophoresis: an alternative drug-delivery system. Med. Device Technol., 9: 32-36.
10. Hirvonen, J., Kalia, Y. N., and Guy, R. H. (1996). Transdermal delivery of peptides by iontophoresis. Nature Biotechnol., 14: 1710-1713.
11. Shofner, R. S., Kaufman, H. E., and Hill, J. M. (1989). New horizons in ocular drug delivery. Ophthalmol. Clin. North Am., 2: 15-24.
12. Sarraf, D., and Lee, D. A. (1994). The role of iontophoresis in ocular drug delivery. J. Ocular Pharm., 10: 69-81.
13. Sasaki, H., Yamamura, K., Mukai, T., Nishida, K., Nakamura, J., Nakashima, M., and Ichikawa, M. (1999). Enhancement of ocular drug penetration. Crit. Rev. Ther. Drug Carrier Syst., 16: 85-146.
14. Shriber, W. J. (1975). The direct current and ion transfer. In: A Manual of Electrotherapy (W. J. Shriber, ed.). Lea & Febiger, Philadelphia, p. 124.
15. Turrell, W. J. (1921). Therapeutic action of the constant current. Proc. R. Soc. Med., 14: 41-52.
16. Morton, W. J. (1898). Cataphoresis of Electric Medicament Surgery.American Technical Book, New York.
17. Leduc, S. (1900). Introduction of medicinal substances into the depth of tissues by electric current. Ann. Electrobiol., 3: 545-550.
18. Leduc, S. (1908). Electric Ions and Their Use in Medicine.Rebman Ltd., London.
19. Wirtz, R. (1908). Die Ionentherapie in der Augenheilkunde. Klin. Monatsbl. Augenheilkd., 46: 543-579.
20. Morisot, L. (1927). L’iontherapie ou ionisation appliquee au traitement des affections ocu-laires. Clin. Ophthalmol., 31: 5-16.
21. Erlanger, G. (1936). On the scientific and practical value of ionization in ophthalmology. Recent advances and researchers. Br. J. Ophthalmol., 20: 213-229.
22. Erlanger, G. (1939). Iontophoretic medication in ophthalmology. Theoretic and practical aspects. Arch. Phys. Ther., 20: 16-24.
23. Erlanger, G. (1954). Iontophoresis: a scientific and practical tool in ophthalmology. Ophthalmologic., 128: 232-246.
24. Von Sallmann, L., and Meyer, K. (1944). Penetration of penicillin into the eye. Arch. Ophthalmol., 31: 1-7.
25. Von Sallmann, L. (1944). Penicillin and sulfadiazine in the treatment of experimental intraocular infections with Staphylococcus aureus andClostridium welchii. Arch. Ophthalmol., 31: 54-61.
26. Von Sallmann, L. (1945). Penetration of penicillin into the eye. Arch. Ophthalmol., 34: 195-201.
27. Witzel, S. H., Fielding, I. Z., and Ormsby, H. L. (1956). Ocular penetration of antibiotics by iontophoresis. Am. J. Ophthalmol., 42: 89-95.
28. Ichihashi, T. (1936). Effect of drugs on the sweat glands by cataphoresis and an effective method for suppression of local sweating: Observation on the effect of diaphoretics and adiaphoretics. J. Oriental Med., 25: 101-102.
29. Gibson, L. E., and Cooke, R. E. (1959). A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics., 23: 545-549.
30. Carter, E. P., Barrett, A. D., Heeley, A. F., and Kuzemko, J. A. (1984). Improved sweat test method for the diagnosis of cystic fibrosis. Arch. Dis. Chil., 59: 919-922.
31. Hall, S. K., Stableforth, D. E., and Green, A. (1990). Sweat sodium and chloride concentrations-essential criteria for the diagnosis of cystic fibrosis in adults. Ann. Clin. Biochem., 27: 318-320.
32. Sloan, J. B., and Soltani, K. (1986). Iontophoresis in dermatology: A review. J. Am. Acad. Dermatol., 15: 671-684.
33. Kassan, D. G., Lynch, A. M., and Stiller, M. J. (1996). Physical enhancement of dermatologic drug delivery: Iontophoresis and phonophoresis. J. Am. Acad. Dermatol., 34: 657-666.
34. Stolman, L. P. (1998). Treatment of hyperhidrosis. Dermatol. Clin., 16: 863-869.
35. Murphy, R., and Harrington, C.I. (2000). Treating hyperhidrosis: Iontophoresis should be tried before other treatments (letter). BMJ, 321: 702-703.
36. Gangarosa, L. P., and Park, N. H. (1978). Practical considerations in iontophoresis of fluoride for desensitizing dentin. J. Prosthet. Dent., 39: 173-178.
37. Krauser, J. T. (1986). Hypersensitive teeth. Part II: Treatment. J. Prosthet. Den., 56(3): 307-311.
38. Greenbaum, S. S., and Bernstein, E. F. (1994). Comparison of iontophoresis of lidocaine with a eutetic mixture of lidocaine and prilocaine (EMLA) for topically administered local anesthesia. J. Dermatol. Surg. Oncol., 20: 579-583.
39. Zempsky, W. T., Anand, K. J. S., Sullivan, K. M., Fraser, D., and Cucina, K. (1998). Lidocaine iontophoresis for topical anesthesia before intravenous line placement in children. J. Pediatr., 132: 1061-1063.
40. DeCou, J. M., Abrams, R. S., Hammond, J. H., Lowder, L. R., and Gauderer, W. L. (1999). Iontophoresis: a needle-free, electrical system of local anesthesia delivery for pediatric surgical office procedures. J. Pediatr. Surg., 34: 946-949.
41. Squire, S. J., Kirchhoff, K. T., and Hissong, K. (2000). Comparing two methods of topical anesthesia used before intravenous cannulation in pediatric patients. J. Pediatr. Health Care., 14: 68-72.
42. Hill, J. M., O’Callaghan, R. J., and Hobden, J. A. (1993). Ocular iontophoresis. In: Ophthalmic Drug Delivery Systems(A. K. Mitra, ed.). Marcel Dekker, New York, pp. 331-354.
43. Callegan, M. C., O’Callaghan, R. J., and Hill, J. M. (1994). Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin. Pharmacokinet., 27: 129-149.
44. Pillai, O., Nair, V., Poduri, R., and Panchagnula, R. (1999). Transdermal iontophoresis. Part II: Peptide and protein delivery. Methods Find. Exp. Clin. Pharmacol., 21: 229-240.
45. Jones, R. F., and Maurice, D. M. (1966). New methods of measuring the rate of aqueous flow in man with fluorescein. Exp. Eye Res., 5: 208-220.
46. Starr, P. A. J. (1966). Changes in aqueous flow determined by fluorophoto-metry. Trans. Ophthalmol. Soc. U.K., 86: 639-646.
47. Holm, O. (1968). A photogrammetric method for estimation of the pupillary aqueous flow in the living human eye. I. Acta Ophthalmol., 46: 254-277.
48. Brubaker, R. F. (1982). The flow of aqueous humor in the human eye. Trans. Am. Ophthalmol. Soc., 80: 391-474.
49. Latina, M. A., Dobrogowski, M., March, W. F., and Birngruber, R. (1990). Laser sclerostomy by pulsed-dye laser and goniolens. Arch. Ophthalmol., 108: 1745-1750.
50. Latina, M. A., Melamed, S., March, W. F., Kass, M. A., and Kolker, A. E. (1992). Gonioscopic Ab Interno Laser Sclerostomy. A pilot study in glaucoma patients. Ophthalmolog., 99: 1736-1744.
51. Melamed, S., Solomon, A., Neumann, D., Hirsch, A., Blumenthal, M., and Belkin, M. (1993). Internal sclerostomy using laser ablation of dyed sclera in glaucoma patients: a pilot study. Br. J. Ophthalmol., 77; 139-144.
52. Grossman, R. E., Sarraf, D., and Lee, D. A. (1993). Iontophoresis of methylene blue for gonioscopic pulsed dye laser sclerostomy. J. Ocul. Pharmacol., 9: 277-285.
53. Sarraf, D., and Lee, D. A. (1993). Iontophoresis of reactive black 5 for pulsed dye laser sclerostomy. J. Ocul Pharmacol. Ther., 9: 25-33.
54. Kitazawa, Y., Nose, H., and Horie, T. (1973). The effects of chemical sympathectomy on intraocular pressure of the normal human subjects. Acta Soc. Ophthalmol. Jpn., 77: 1901-1903.
55. Kitazawa, Y., and Horie, T. (1974). Denervation supersensitivity induced by chemical sympathectomy with 6-hydroxydopamine. Jpn. J. Ophthalmol., 18: 109-118.
56. Kitazawa, Y., Nose, H., and Horie, T. (1975). Chemical sympathectomy with 6-hydroxydopamine in the treatment of primary open-angle glaucoma. Am. J. Ophthalmol., 79: 98-103.
57. Watanabe, H., Levene, R. Z., and Bernstein, M. R. (1977). 6-Hydroxydopamine therapy in glaucoma. Trans. Am. Acad. Ophthalmol. Otolaryngol., 83: 69-77.
58. Colasanti, B. K., and Trotter, R. R. (1977). Enhanced ocular penetration of the methyl ester of alpha-methyl-para-tyrosine after iontophoresis. Arch. Int. Pharmacodyn. Ther., 228: 171-176.
59. Blumenkranz, M. S., Clafin, A., and Hajek, A. S. (1984). Selection of therapeutic agents for intraocular proliferative disease. Arch. Ophthalmol., 102: 598-604.
60. Kondo, M., and Araie, M. (1989). Iontophoresis of 5-fluorouracil into the conjunctiva and sclera. Invest. Ophthalmol. Vis. Sci., 30: 583-585.
61. Zempsky, W. T., and Ashburn, M. A. (1998). Iontophoresis: noninvasive drug delivery. Am. J. Anesthesiol., 25: 158-162.
62. Sisler, H. A. (1978). Iontophoretic local anesthesia for conjunctival surgery. Ann. Ophthalmol., 10: 597-598.
63. Meyer, D. R., Lindberg, J. V., and Vasquez, R. J. (1990). Iontophoresis for eyelid anesthesia. Ophthalmic Surg., 21: 845-848.
64. Havener, W. H. (1978). Corticosteroid therapy. In: Ocular Pharmacology, 4th ed. CV Mosby, St. Louis, pp. 143-174.
65. Lachaud, J. P. (1965). Considerations on the use of corticosteroids by ionization in certain ocular diseases. Bull. Soc. Ophthalmol. Franc., 65: 84-89.
66. Lam, T. T., Edward, D. P., Zhu, X., and Tso, M. O. M. (1989). Transscleral iontophoresis of dexamethasone. Arch. Ophthalmol., 107: 1368-1371.
67. Behar-Cohen, F. F., Parel, J.-M., Pouliquen, Y., Thillaye-Goldenberg, B., Goureau, O., Heydolph, S., Courtois, Y., and DeKozak, Y. (1997). Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp. Eye Res., 65: 533-545.
68. Pagano, G., Bruno, A., Cavallo-Perin, P., Cesco, L., and Imbimbo, B. (1989). Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Arch. Int. Med., 149: 1091-1098.
69. Yoshida, M., Yoshimura, N., Hangai, M., Tanihara, H., and Honda, Y. (1994). Interleukin-1 a, interleukin-1 b, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci., 35: 1107-1113.
70. Grossman, R. E., Chu, D. F., and Lee, D. A. (1990). Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis. Invest. Ophthalmol. Vis. Sci., 31: 909-916.
71. Fishman, P. H., Jay, W. M., Hill, J. M., Rissing, J. P., and Shockley, R. K. (1984). Iontophoresis of gentamicin into aphakic rabbit eyes: sustained vitreal levels. Invest. Ophthalmol. Vis. Sci., 25: 343-345.
72. Hughes, L., and Maurice, D. (1984). A fresh look at iontophoresis. Arch. Ophthalmol., 102; 1825-1829.
73. Frucht-Pery, J., Solomon, A., Doron, R., Ever-Hadani, P., Manor, O., and Shapiro, M. (1996). Efficacy of iontophoresis in the rat cornea. Graefes Arch. Clin. Exp. Ophthalmol., 234: 765-769.
74. Frucht-Pery, J., Goren, D., Solomon, A., Siganos, C. S., Mechoulam, H., Ever-Hadani, P., and Shapiro, M. (1999). The distribution of gentamicin in the rabbit cornea following iontophoresis to the central cornea. J. Ocular Pharm. Therapeut., 15: 251-256.
75. Barza, M., Peckman, C., and Baum, J. (1986). Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmolog., 93: 133-139.
76. Barza, M., Peckman, C., and Baum, J. (1987). Transscleral iontophoresis as an adjunctive treatment for experimental endophthalmitis. Arch. Ophthalmol., 105: 1418-1420.
77. Burstein, N. L., Leopold, I. H., and Bernaacchii, D. B. (1985). Transscleral iontophoresis of gentamicin. J. Ocul. Pharmacol., 1: 363-368.
78. Barza, M. M., Peckman, C., and Baum, J. (1987). Transscleral iontophoresis of gentamicin in monkeys. Invest. Ophthalmol. Vis. Sci., 28: 1033-1036.
79. Rootman, D. S., Hobden, J. A., Jantzen, J. A., Gonzales, V. R., O’Callaghan, R. J., and Hill, J. M. (1988). Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit. Arch. Ophthalmol., 106: 262-265.
80. Hobden, J. A., Rootman, D. S., O’Callaghan, R. J., and Hill, J. M. (1988). Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas. Antimicrob. Agents Chemother., 32: 978-981.
81. Rootman, D. S., Jantzen, J. A., Gonzalez, J. R., Fischer, M., Beuerman, R., and Hill, J. M. (1988). Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Invest. Ophthalmol. Vis. Sci., 29: 1397-1401.
82. Hobden, J. A., O’Callaghan, R. J., Hill, J. M., Reidy, J. J., Rootman, D. S., and Thompson, H. W. (1989). Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa. Curr. Eye Res., 8: 1163-1169.
83. Physician’s Desk Reference. (1977). Medical Economics Company, Montvale, N.J.
84. Hobden, J. A., Reidy, J. J., O’Callaghan, R. J., and Hill, J. M. (1990). Ciprofloxacin iontophoresis for aminoglycoside-resistant Pseudomonas keratitis. Invest. Ophthalmol. Vis. Sci., 31: 1940-1944.
85. Yoshizumi, M. O., Cohen, D., Verbukh, I., Leinwand, M., Kim, J., and Lee, D. A. (1991). Experimental transscleral iontophoresis of ciprofloxacin. J. Ocular Pharm., 7: 163-167.
86. Choi, T. B., and Lee, D. A. (1988). Transscleral and transcorneal iontophoresis of vancomycin in rabbit eyes. J. Ocular Pharmacol., 4: 153-164.
87. Grossman, R., and Lee, D. A. (1989). Transscleral and transcorneal iontophoresis of ketoconazole in the rabbit eye. Ophthalmolog., 96: 724-729.
88. Boniuk, I. (1972). The cytomegaloviruses and the eye. Int. Ophthalmol. Clin., 12: 169-190.
89. Miller, R. F., Howard, M. R., Frith, P., Perrons, C. J., Pecorella, I., and Lucas, S. B. (2000). Herpes-virus infection of eye and brain in HIV. Sex. Transm. Inf., 76: 282-286.
90. Friedman, A. H., Orellana, J., Freeman, W. R., Luntz, M. H., Starr, M. B., Tapper, M. L., et al. (1983). Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS). Br. J. Ophthalmol., 67: 372-380.
91. Oberg, B. (1983). Antiviral effects of phosphonoformate (PFA foscarnet sodium). Pharmacol. Ther., 19: 387-415.
92. Fannibg, M. M., Read, S. E., Benson, M., Vas, S., Rachlis, A., Kozousek, V., et al. (1990). Foscarnet therapy of cytomegalovirus retinitis in AIDS. J. Acquir. Immune Defic. Syndr., 3: 472-479.
93. Jacobson, M. A., and O’Donnell, J. J. (1991). Approaches to the treatment of cytomegalovirus retinitis: Ganciclovir and Foscarnet. J. Acquir. Immune Defic., Syndr, 4 (Suppl. 1): S11-S15.
94. She, S.-C., Peyman, G. A., and Schulman, J. A. (1988). Toxicity of intravitreal injection of foscarnet in the rabbit eye. Int. Ophthalmol., 12: 151-154.
95. Diaz-Llopis, M., Chipont, E., Sanchez, S., Espana, E., Navea, A., and Menezo, J. L. (1992). Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am. J. Ophthalmol., 114: 742-747.
96. Kreiger, A. E., Foos, R. Y., and Yoshizumi, M. O. (1992). Intravitreous granulation tissue and retinal detachment following pars plana injection for cytomegalovirus retinopathy. Graefe’s Arch. Clin. Exp. Ophthalmol., 230: 197-198.
97. Sarraf, D., Equi, R. A., Holland, G. N., Yoshizumi, M. O., and Lee, D. A. (1993). Transscleral iontophoresis of foscarnet. Am. J. Ophthalmol., 115: 748-754.
98. Yoshizumi, M. O., Lee, D. A., Sarraf, D. A., Equi, R. A., and Verdon, W. (1995). Ocular toxicity of iontophoretic foscarnet in rabbits. J. Ocul. Pharmacol. Ther., 11: 183-189.
99. Anand, R., Nightingale, S. D., Fish, R. H., Smith, T. J., and Ashton, P. (1993). Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch., Ophthalmol., 111: 223-227.
100. Yoshizumi, M. O., Roca, J. A., Lee, D. A., Lee, G., and Gomez, I. (1996). Ocular iontophoretic supplementation of intravenous foscarnet therapy. Am. J. Ophthalmol., 122: 86-90.
101. Yoshizumi, M. O., Dessouki, A., Lee, D. A., and Lee, G. (1997). Determination of Ocular toxicity in multiple applications of foscarnet iontophoresis. J. ocular Pharmacol. Therapeut., 13: 529-536.
102. Hill, J. M., Wen, R., and Halford, W. P. (1998). Pathogenesis and molecular biology of ocular HSV in the rabbit. In: Herpes Simplex Virus Protocols (MS Brown, AR Maclean, eds.). Humana Press, Inc., Totowa, NJ, pp. 291-315.
103. Kaufman, H. E., and Rayfield, M. A. (1988). In: The Cornea: Viral Conjunctivitis and Keratitis(H. E. Kaufman, B. A. Barron, M. B. McDonald, and S. R. Waltman, eds.). Churchill Livingstone, New York, pp. 299-331.
104. Hill, J. M., Gangarosa, L. P., and Park, N. H. (1977). Iontophoretic application of antiviral chemotherapeutic agents. Ann. NY Acad. Sci., 284: 604-612.
105. Hill, J. M., Park, N. H., Gangarosa, L. P., Hull, D. S., Tuggle, C. L., Bowman, K., and Green, K. (1978). Iontophoretic application of vidarabine monophosphate into rabbit eyes. Invest. Ophthalmol. Vis. Sci., 17: 473-476.
106. Kwon, B. S., Gangarosa, L. P., Park, N. H., Hull, D. S., Fineberg, E., Wiggins, C., and Hill, J. M. (1979). Effects of iontophoretic and topical application of antiviral agents in treatment of experimental HSV-1 keratitis in rabbits. Invest. Ophthalmol. Vis. Sci., 18: 984-988.
107. Hill, J. M., Kwon, B. S., Burch, K. D., deBack, J., Whang, I., Jones, G. T., Luke, B., Andrews, P., Harp, R., Shimomura, Y., Hull, D. S., and Gangarosa, L. P. (1982). Acyclovir and vidarabine monophosphate: a comparison of iontophoretic and intravenous administration for the treatment of HSV-1 stromal keratitis. Am. J. Med., 73: 300-304.
108. Stevens, J. G., Newburn, A. B., and Cook, M. L. (1972). Latent herpes simplex virus from trigeminal ganglia of rabbits with recurrent eye infection. Nature (New Biology., 235: 216-217.
109. Stevens, J. G. (1994). Overview of herpesvirus latency. Semi. Virol., 5: 191-196.
110. Rivera, L., Beuerman, R. W., and Hill, J. M. (1988). Corneal nerves contain intra-axonal HSV-1 after virus reactivation by epinephrine iontophoresis. Curr. Eye Res., 7: 1001-1008.
111. Schmidt, D. D., Zyzanski, S., Ellner, J., Kumar, M. L., and Arno, J. (1985). Stress as a precipitating factor in subjects with recurrent herpes labialis. J. Family Pract., 20: 359-366.
112. Varnell, E. D., Kaufman, H. E., Hill, J. M., and Thompson, H. W. (1995). Cold stress-induced recurrences of herpetic keratitis in the squirrel monkey. Invest. Ophthalmol. Vis. Sci., 36: 1181-1183.
113. Hill, J. M., Garza, H. H., Helmy, M. F., Cook, S. D., Osborne, P. A., Johnson, E. M., Thompson, H. W., Green, L. C., O’Callaghan, R. J., and Gebhardt, B. M. (1997). Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. J. Neurovirol., 3: 206-211.
114. Stanberry, L. R. (1994). Animal models and HSV latency. Sem. Virol., 5: 213-219.
115. Hill, J. M., Haruta, Y., and Rootman, D. S. (1987). Adrenergically induced recurrent HSV-1 corneal epithelial lesions. Curr. Eye Res., 6: 1065-1071.
116. Hill, J. M., Rayfield, M. A., and Haruta, Y. (1987). Strain specificity of spontaneous and adrenergically induced HSV-1 ocular reactivation in latently infected rabbits. Curr. Eye Res., 6: 91-97.
117. Hill, J. M., Shimomura, Y., Kwon, B. S., and Gangarosa, L. P. (1986). Iontophoresis of epinephrine isomers to rabbit eyes induced HSV-1 ocular shedding. Invest. Ophthalmol. Vis. Sci., 26: 1299-1303.
118. Kwon, B. S., Gangarosa, L. P., Burch, K. D., deBack, J., and Hill, J. M. (1981). Induction of ocular herpes simplex virus shedding by iontophoresis of epinephrine into rabbit cornea. Invest. Ophthalmol. Vis. Sci., 21: 442-449.
119. Kwon, B. S., Gangarosa, L. P., Green, K., and Hill, J. M. (1982). Kinetics of ocular herpes simplex virus shedding induced by epinephrine iontophoresis. Invest. Ophthalmol. Vis. Sci., 22: 818-821.
120. Willey, D. E., Trousdale, M. D., and Nesburn, A. B. (1984). Reactivation of murine latent HSV infection by epinephrine iontophoresis. Invest. Ophthalmol. Vis. Sci, 25: 945-950.
121. Gordon, Y. J., Araullo-Cruz, T. P., Romanowski, E., Ruziczka, L., Balouris, C., Oren, J., Cheng, K. P., and Kim, S. (1986). The development of an improved murine iontophoresis reactivation model for the study of HSV-1 latency. Invest. Ophthalmol. Vis. Sci., 27: 1230-1234.
122. Varnell E. D., Kaufman, H. E., Hill, J. M., and Wolf, R. H. (1987). A primate model for acute and recurrent herpetic keratitis. Curr. Eye Res., 6: 277-279.
123. Rootman, D. S., Haruta, Y., and Hill, J. M. (1990). Reactivation of HSV-1 in primates by transcorneal iontophoresis of adrenergic agents. Invest. Ophthalmol. Vis. Sci., 31: 597-600.
124. Hill, J. M., Kwon, B. S., Shimomura, Y., Colborn, G. L., Yaghmai, F., and Gangarosa, L. P. (1983). Herpes simplex virus recovery in neural tissues after ocular HSV shedding induced by epinephrine iontophoresis to the rabbit cornea. Invest. Ophthalmol. Vis. Sci., 24: 243-247.
125. Shimomura, Y., Gangarosa, L. P., Sr., Kataoka, M., and Hill, J. M. (1983). HSV-1 shedding by iontophoresis of 6-hydroxydopamine followed by topical epinephrine. Invest Ophthalmol Vis. Sci., 24: 1588-1594.
126. Hill, J. M., Dudley, J. B., Shimomura, Y., and Kaufman, H. E. (1986). Quantitation and kinetics of induced HSV-1 ocular shedding. Curr. Eye. Re., 5: 241-246.
127. Haruta, Y., Rootman, D. S., and Hill, J. M. (1988). Recurrent HSV-1 corneal epithelial lesions by timolol iontophoresis in latently infected rabbits. Invest. Ophthalmol. Vis. Sci., 29: 387-392.
128. Hill, J. M., Shimomura, Y., Dudley, J. B., Berman, E., Haruta, Y., Kwon, B. S., and Maguire, L. J. (1987). Timolol induces HSV-1 ocular shedding in the latently infected rabbit. Invest. Ophthalmol. Vis. Sci., 28: 585-590.
129. Rootman, D. S., Haruta, Y., Hill, J. M., and Kaufman, H. E. (1989). Trifluridine decreases ocular HSV-1 recovery, not recurrent HSV-1 lesions following timolol iontophoresis in the rabbit. Invest. Ophthalmol. Vis. Sci., 30: 678-683.
130. Kaufman, H. E., Varnell, E. D., Gebhardt, B. M., Thompson, H. W., and Hill, J. M. (1996). Propranolol suppression of ocular HSV-1 recurrence and associated corneal lesions following spontaneous reactivation in the rabbit. Curr. Eye Res., 9: 1015-1021.
131. Gebhardt, B. M., and Kaufman, H. E. (1995). Propranolol suppresses reactivation of herpesvirus. Antiviral Res., 27: 255-261.
132. Garza, H. H., Jr., and Hill, J. M. (1997). Effect of a beta-adrenergic antagonist, propranolol, on induced HSV-1 ocular recurrence in latently infected rabbits. Curr. Eye Res., 16: 453-458.
133. Haruta, Y., Rootman, D. S., Xie, L., Kiritoshi, A., and Hill, J. M. (1989). Recurrent HSV-1 corneal lesions in rabbits induced by cyclophosphamide and dexamethasone. Invest. Ophthalmol. Vis. Sci., 30: 371-376.
134. Wagner, E. K., and Bloom, D. C. (1997). Experimental investigation of herpes simplex virus latency. Clin. Microbiol. Rev., 10: 419-443.
135. Miller, C. S., Danaher, R. J., and Jacob, R. J. (1998). Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Crit. Rev. Oral Biol. Me., 9: 541-562.
136. Millhouse, S., and Wigdhal, B. (2000). Molecular circuitry regulating herpes simplex virus type 1 latency in neurons. J. Neurovirol., 6: 6-24.
137. Stevens, J. G., Wagner, E. K., Devi-Rao, G. B., Cook, M. L., and Feldman, L. T. (1987). RNA complementary to a herpesvirus a gene mRNA is prominent in latently infected neurons. Scienc., 235: 1056-1059.
138. Spivak, J. G., and Fraser, N. W. (1987). Detection of herpes simplex virus type 1 transcripts during latent infection in mice. J. Virol., 61: 3841-3847.
139. Javier, R. T., Stevens, J. G., Dissette, V. B., and Wagner, E. K. (1988). A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state. Virolog., 166: 254-257.
140. Stevens, J. G. (1989). Human herpesviruses: a consideration of the latent state. Microbiol. Rev., 53: 318-332.
141. Rock, D. L., Nesburn, A. B., Ghiasi, H., Ong, I., Lewis, T. L., Lokensgard, J. R., and Wechsler, S. L. (1987). Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J. Viro., 61: 3820-3826.
142. Cook, S. D., Hill, J. M., Lynas, C., and Maitland, N. J. (1991). Latency-associated transcripts in corneas and ganglia of HSV-1 infected rabbits. Br. J. Ophthalmol., 75: 644-648.
143. Croen, K. D., Ostrove, J. M., Dragovic, L. J., Smialek, J. E., and Straus, S. E. (1987). Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene “anti-sense” transcript by in situ hybridization. N. Engl. J. Med., 317: 1427-1432.
144. Kaye, S. B., Lynas, C., Patterson, A., Risk, J. M., McCarthy, K., and Hart, C. A. (1991). Evidence of herpes simplex viral latency in the human cornea. Br. J. Ophthalmol., 75: 195-200.
145. Fraser, N. W., Block, T. M., and Spivak, J. G. (1992). The latency-associated transcripts of herpes simplex virus: RNA in search of a function. Virology191: 1-8.
146. Wagner, E. K., Flanagan, W. M., Devi-Rao, G., Zhang, Y. F., Hill, J. M., Anderson, K. P., and Stevens, J. G. (1988). The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection. J. Virol., 62: 4577-4585.
147. Block, T. M., and Hill, J. M. (1997). The latency associated transcripts (LAT) of herpes simplex virus: still no end in sight. J. Neurovirol., 3: 313-321.
148. Farrell, M. J., Dobson, A. T., and Feldman, L. T. (1991). Herpes simplex virus-latency-associated transcript is a stable intron. Proc. Natl. Acad. Sci. US., 88: 790-794.
149. Hill, J. M., Sedarati, F., Javier, R. T., Wagner, E. K., and Stevens, J. G. (1990). Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology, 174: 117-125.
150. Hill, J. M., Maggioncalda, J. B., Garza, H. H., Jr., Su, Y.-H., Fraser, N. W., and Block, T. M. (1996). In vivo epinephrine reactivation of ocular herpes simplex virus type 1 in the rabbit is correlated to a 370-base-pair region located between the promoter and the 5′ end of the 2.0-kilobase latency-associated transcript. J. Virol., 70: 7270-7274.
151. Bloom, D. C., Devi-Rao, G. B., Hill, J. M., Stevens, J. G., and Wagner, E. K. (1994). Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo. J. Virol., 68: 1283-1292.
152. Bloom, D. C., Stevens, J. G., Hill, J. M., and Tran, R. K. (1997). Mutagenesis of a cAMP response element within the latency-associated transcript promoter of HSV-1 reduces adrenergic reactivation. Virolog., 236: 202-207.
153. Colgin, M. A., Smith, R. L., and Wilcox, C. L. (2001). Inducible cyclic AMP early repressor produces reactivation of latent herpes simplex virus type 1 in neurons in vitro. J. Virol., 75: 2912-2920.
154. Loutsch, J. M., Perng, G.-C., Hill, J. M., Zheng, X., Marquart, M. E., Block, T. M., Ghiasi, H., Nesburn, A. B., and Wechsler, S. L. (1999). Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J. Viro., 73: 767-771.
155. Zheng, X., Marquart, M. E., Loutsch, J. M., Shah, P., Sainz, B., Ray, A., O’Callaghan, R. J., Kaufman, H. E., and Hill, J. M. (1999). HSV-1 migration in latently infected and naive rabbits after penetrating keratoplasty. Invest. Ophthalmol. Vis. Sci., 40: 2490-2497.
156. McGill, J. (1991). Herpes simplex latency and the eye. Br. J. Ophthalmol., 75: 641-642.
157. Cook, S. D., Ophth, F. C., and Hill, J. M. (1991). Herpes simplex virus: molecular biology and the possibility of corneal latency. Surv. Ophthalmol., 36: 140-148.
158. Bloom, D. C., Hill, J. M., Devi-Rao, G., Wagner, E. K., Feldman, L. T., and Stevens, J. G. (1996). A 348-base pair region in the latency-associated transcript facilitates herpes simplex virus type 1 reactivation. J. Virol., 70: 2449-2459.
159. Perng, G.-C., Slanina, S. M., Ghiasi, H., Nesburn, A. B., and Wechsler, S. L. (1996). A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J. Virol., 70: 2014-2018.
160. Hill, J. M., Garza, H. H., Su, Y. H., Meegalla, R., Hanna, L. A., Loutsch, J. M., Thompson, H. W., Varnell, E. D., Bloom, D. C., and Block, T. M. (1997). A 437-base pair deletion at the beginning of the latency-associated transcript promoter significantly reduced adrenergically induced herpes simplex virus type 1 ocular reactivation in latently infected rabbits. J. Virol., 71: 6555-6559.
161. Devi-Rao, G. B., Aquilar, J. S., Rice, M. K., Garza, H. H., Jr., Bloom, D. C., Hill, J. M., and Wagner, E. K. (1997). Herpes simplex virus genome replication and transcription during induced reactivation in the rabbit eye. J. Virol., 71: 7039-7047.
162. Behar-Cohen, F. F., Savoldelli, M., Parel, J. M., Goureau, O., Thillaye-Goldenberg, B., Courtois, Y., Pouliquen, Y., and de Kozak, Y. (1998). Reduction of corneal edema in endotoxin-induced uveitis after application of L-NAME as nitric oxide synthase inhibitor in rats by iontophoresis. Invest. Ophthalmol. Vis. Sci., 39: 897-904.
163. Martin, R. E., Loutsch, J. M., Garza, H. H., Jr., Boedeker, D. J., and Hill, J. M. (1999). Iontophoresis of lysophosphatidic acid into rabbit cornea induces HSV-1 reactivation: evidence that neuronal signaling changes after infection. Mol. Vis., 5: 36, www.molvis.org/molvis/v5/p36/.
164. Dowd, N. P., Day, F., Timon, D., Cunningham, A. J., and Brown, L. (1999). Iontophoretic vincristine in the treatment of postherpetic neuralgia: A doubleblind, randomized, controlled trial. J. Pain Symptom Manage., 17: 175-180.
165. Santi, P., Volpato, N. M., Bettini, R., Catellani, P. L., Massimo, G., and Colombo, P. (1997). Transdermal iontophoresis of salmon calcitonin can reproduce the hypocalcemic effect of intravenous administration. Farmaco, 52: 445-448.
166. Chang, S. L., Hofmann, G. A., Zhang, L., Deftos, L. J., and Banga, A. K. (2000). Transdermal iontophoretic delivery of salmon calcitonin. Int. J. Pharm., 200: 107-113.
167. Mize, N. K., Buttery, M., Daddona, P., Morales, C., and Cormier, M. (1997). Reverse iontophoresis: monitoring prostaglandin E2 associated with cutaneous inflammation in vivo. Exp. Dermatol., 6: 298-302.
168. Merino, V., Lopez, A., Hochstrasser, D., and Guy, R. H. (1999). Noninvasive sampling of phenylalanine by reverse iontophoresis. J. Control Releas., 61: 6569.
169. Brasch, J., Huttemann, M., and Proksch, E. (2000). Iontophoresis of nickel elicits a delayed cutaneous response in sensitized individuals that is similar to an allergic patch test reaction. Contact Dermatiti., 42: 36-41.
170. Asahara, T., Shinomiya, K., Naito, T., and Shiota, H. (1999). Induction of genes into the rabbit eye by iontophoresis. Acta Soc. Ophthalmol. Jpn., 103: 178-186.
171. Chapon, P., Voigt, M., Gautier, S., Behar-Cohen, F., O’Grady, G., and Parel, J.-M. (1999). Intraocular tissues pharmacokinetics of ganciclovir transscleral Coulomb Controlled iontophoresis in rabbits (abstr). IOVS/ARVO, 40(4): S189.
172. Chauvaud, D., Behar-Cohen, F., Parel, J. M., and Renard, G. (2000). Transscleral iontophoresis of corticosteroids: Phase II clinical trial (abstr). IOVS/ARVO41(4): S79.
173. Hayden, B. C., Voigt, M., Murray, T. G., Hernandez, E., Parel, J.-M., Cicciarelli, N., Feuer, W., Fulton, L., and O’Brien, J. M. (2000). Iontophoretic delivery of carboplatin in the treatment of murine transgenic retinoblastoma (abstr). IOVS/ARVO41(4): S788.